Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers
WebcastFaculty
OVERVIEW
Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers is organized by Physicians Education Resource, LLC (PER) and will be held during Aug 31, 2017 - Aug 31, 2018.
The target audience for this medical event is directed toward medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Overview :
Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers features a summary of clinical evidence guiding best practices in the use of immunotherapies for the treatment of patients with solid tumors. Key data leading to approval of immunotherapies will be presented, along with future directions, including combinations, new immunotherapeutic targets, and the investigation of immunotherapy in earlier stages of disease. Approaches to the mitigation and management of immune-related adverse events will also be discussed. Interactive clinical vignettes are followed by short video interviews with leading experts in the management of patients with lung, head and neck, and bladder cancer. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Detail specific anti–CTLA-4, anti–PD-1, and anti–PD-L1 mechanistic approaches in the context of their developmental rationale to target solid tumors
• Apply evidence on single-agent/combination immuno-oncology strategies, and explain their impact on decision making in the evolving fields of lung cancer, head and neck squamous cell cancer (HNSCC), and bladder cancer
• Delineate practical methods to individualize the application of immuno-oncology strategies based on PD-L1 testing results
• Develop multidisciplinary action steps to proactively mitigate the impact of immune-related adverse events in patients who receive checkpoint inhibitors for the treatment of non–small cell lung cancer (NSCLC), HNSCC, and bladder cancer
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Overview :
Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers features a summary of clinical evidence guiding best practices in the use of immunotherapies for the treatment of patients with solid tumors. Key data leading to approval of immunotherapies will be presented, along with future directions, including combinations, new immunotherapeutic targets, and the investigation of immunotherapy in earlier stages of disease. Approaches to the mitigation and management of immune-related adverse events will also be discussed. Interactive clinical vignettes are followed by short video interviews with leading experts in the management of patients with lung, head and neck, and bladder cancer. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Detail specific anti–CTLA-4, anti–PD-1, and anti–PD-L1 mechanistic approaches in the context of their developmental rationale to target solid tumors
• Apply evidence on single-agent/combination immuno-oncology strategies, and explain their impact on decision making in the evolving fields of lung cancer, head and neck squamous cell cancer (HNSCC), and bladder cancer
• Delineate practical methods to individualize the application of immuno-oncology strategies based on PD-L1 testing results
• Develop multidisciplinary action steps to proactively mitigate the impact of immune-related adverse events in patients who receive checkpoint inhibitors for the treatment of non–small cell lung cancer (NSCLC), HNSCC, and bladder cancer
Additional details will be posted as soon as they are available.
SPECIALITIES
OncologyImmunotherapies
Quick Links